Skip to main content
Journal of Advanced Pharmaceutical Technology & Research logoLink to Journal of Advanced Pharmaceutical Technology & Research
. 2021 Oct 20;12(4):311–320. doi: 10.4103/japtr.JAPTR_159_21

A current novel perspective approach for coronavirus disease-2019 pandemic outbreak

Md Faruque Ahmad 1, M Ali 1, Abdul Rahman A Alsayegh 1, Sarfaraz Ahmad 2, Nawazish Alam 2, Shadma Wahab 3, Md Sajid Ali 4, Md Tanwir Athar 5,6,
PMCID: PMC8588910  PMID: 34820303

Abstract

Coronavirus disease-2019 is a serious health threat around the globe. Across the world, approximately 142 million people were infected, and three million deaths happened. The fast propagation is also associated with constant anxiety, mental stress, and discomfort in public and health-care professionals. Lack of approved drugs regimen to combat the pandemic challenge concretely is a challenging project for all who are committed to developing remedial assistance. However, the successful development of three vaccines gives a solid roadmap to combat this disease. In this review, we highlighted the current development and challenges of this pandemic.

Keywords: Corona vaccine, coronavirus, coronavirus disease-2019, epidemiology, pathogenesis, virology

INTRODUCTION

World Health Organization (WHO) confirmed that viral infections are emerging as a serious public health threat. Currently, the virus, coronavirus disease-2019 (COVID-19) has affected so many countries, areas, or territories over 142 million people infected across the world.[1] This disease is caused by a severe acute respiratory syndrome (SARS) that is commonly known as SARS-coronavirus-2 (CoV2).[2] The disease is first started from the city of Wuhan in China in December-2019. Starting from the first identification, it was spread rapidly and a number of cases and death were reported.[3] As of January 30, 2020, the WHO confirmed this outbreak as an international public health emergency.[4] On March 11, 2020, the WHO declared COVID-19 as a pandemic.[5] It has been observed in COVID-19 characteristics that average patients ages are 49–56 years, the mean incubation period is 5.2 days, and the median time of 14 days is noted from the first symptom to death. Male are more than female in hospitalized patients from 54% to 73%. However in the second wave, children are also getting affected by this pandemic. Still, the elders are more susceptible to this disease than the younger. Characteristics of COVID-19 is in Figure 1.[6]

Figure 1.

Figure 1

An outline highlighting its viral characteristic, animal host, incubation time, and clinical manifestation of coronavirus disease-2019 virus

EPIDEMIOLOGY

Pandemic COVID-19 has been spread out globally. As of December 31, the local health authority announced epidemiological alerts and markets were closed all the sudden measures adopted on January 1, 2020. Further, 41 hospitalized patients were identified and confirmed COVID-19 infection on 2nd January.[7] The National Health Commission of China confirmed the death of 17 patients of COVID-19 on January 22, 2020. On January 25, 20202, a total number of 1975 cases and 56 death were confirmed from Mainland China.[8] On January 30, 2020, the cases of this disease increased to 7734. As of February 12, 2020, Taiwan centers for disease control also announced the data comprising the records of 28 countries having 45,167 cases a global update.[9] As of February 23, 2020, it was reported that the number of cases increased 1879 times in comparison to January 10, 2020.[10]

The cases were rapidly increased in aberrant ways throughout the world. At the time of data collection for the manuscript on April 12, 2021, the WHO reported confirmed cases 142,557,268 including 3,037,398 deaths globally. Figures 2 and 3 showed the pattern of the global case of COVID infection and related deaths. The COVID-19 spread to 219 countries, areas, and territories. The WHO also revealed recorded statistics on a continent wise, which comprised as 49,564,187 in Europe, 60,006,538 in America, 8,609,860 in Eastern Mediterranean, 2,258,194 in Western Pacific, 18,562,170 in South East Asia, and 3,236,379 in Africa [Figure 4].[11] However, after the start of the vaccination program in the world, a total of 889,827,023 vaccine doses has also been administered to the world population until April 21, 2021.

Figure 2.

Figure 2

Worldwide accumulative cases of coronavirus disease-2019 pandemic (March–April 2021) as per the WHO report

Figure 3.

Figure 3

Worldwide accumulative deaths of coronavirus disease-2019 pandemic (March–April 2021) as per World Health Organization report

Figure 4.

Figure 4

The cases of corona pandemic in World Health Organization region. Data showed that America is most affected by this disease (42.19%) followed by Europe (34.85%), South-East Asia (13.05%), Eastern Mediterranean (6.05%), Africa (2.28%), and Western Pacific (1.59%)

VIROLOGY

Genomic description

COVID-19 virus is a single-stranded RNA virus 30–32 kb genome having a lot of natural roots.[12] The current strain of the virus comprising four subtypes as alpha (α), beta (β), gamma (γ), and delta (δ) categories where α and β were reported to have enough virulence capacities to infect human beings.[13] The structural proteins of the new virus include spike, nucleocapsid, envelope, and membrane, which constitute a complete structure and mechanistic cascades towards binding and proliferation [Figure 5].[14]

Figure 5.

Figure 5

A schematic diagram of coronavirus disease virion showing RNA (single stranded) containing protein N, embedded inside membrane protein (m) with a projection of spike glycoprotein (s) and hemagglutinin-esterase dimer. The figure is made with BioRender (https://biorender.com/)

Physiochemical properties

The appearance of the virus is round in shape, having a diameter of 60–100 nm with deactivating properties either by ultraviolet or heating at 56°C. The virus is believed to be killed after application of the usual disinfectant.[15] Observational studies confirm the stability of the virus on plastic and stainless steel surfaces.[16]

Cellular entry of virus and receptor interaction

Coronavirus and its interaction with the renin–angiotensin–aldosterone system are believed to have a reliable step toward the infection. This interaction between coronavirus and angiotensin-converting enzyme-2 (ACE-2) is also considered a potential stage of infection.[17] The primary role of ACE is converting angiotensin I to produce Ang-(1–9). Moreover, it is also available for binding with the spike protein of CoVs. The binding is due to the presence of N-terminal peptidase domain and C-terminal collectrin domain.[18] COVID-19 is also expressed in other nucleoproteins, polyprotein, and a number of membrane proteins that include RNA polymerase, papain-like protease, and accessory proteins.[19]

CLINICAL MANIFESTATIONS AND DIAGNOSIS

Clinical manifestation

COVID-19 manifestations have been varied from asymptomatic or minor symptoms to severe complaint and finally, they cause death of the patient. Fever, cough, body ache, muscle fatigue myalgia, and dyspnea are the most common symptom while headache, malaise, diarrhea, and rhinitis were reported in this disease.[20]

Diagnosis

Diagnosis of COVID-19 is being carried out through laboratory investigations.[21] The onset of fever, cough, and dyspnea could be primary symptoms for the diagnosis of this disease. The probability of COVID-19 is augmented if patients traveled from the community transmission area or had interacted with a COVID patient as well as the suspected cases in the earlier 14 days. Finally, the suspicious case can be confirmed by performing the various confirmatory tests [Table 1].

Table 1.

Diagnostic test for severe acute respiratory syndrome coronavirus 2 (severe acute respiratory syndrome-coronavirus-2)

Test name Mechanisms/Procedure Interpretation
RT-PCR The RT PCR is used to detect COVID-19 by collecting nasopharyngeal swab specimen Positive result of RT-PCR confirms case
CT-scan CT of the chest is recommended in case of the severe pulmonary disease for detection of viral pneumonia infection CT-scan is being used as a confirmatory test if RT-PCR results could be doubtful
Immunoassay ELISA procedure is being used for the detection of antibodies generated by the immune system of the host This test will be recommended for the patients who have a history of infection, but RT-PCR is negative
Look for other causes Quick flu investigations and the respiratory viral panel is being used to check the other causes of the symptoms Persons having physical contact or suspects traveled or residing to a location of COVID-19 transmission within or prior 14 days

RT: Reverse transcription, PCR: Polymerase chain reaction, CT: Computerized tomography, COVID-19: Coronavirus disease-2019

PATHOGENESIS

The adherence of COVID-19 virus to ACE-2 receptors in type II pneumocytes forms a complex which stimulates inflammation in the lower respiratory tract.[23] This complex is progressed by type 2 transmembrane enzyme protease (TMPRSS2) in a proteolytic manner leading to the disruption and cleaved out of ACE-2, finally, to activate the s-spike protein.[24] The virus genome is uncoated, transcribed, and translated.[25] Studies suggest that the binding patterns and the mode to trigger up the inflammatory cascade are almost common as in the case of earlier strain (SARS-CoV and novel SARS-CoV-2).[26] This membrane inoculation causes diseased cell outcomes and termination of the cilium normalcy at particular sites.[27] Later on, some specific inflammatory mediators were released. These mediators further stimulate macrophages to release the multiple cytokines interleukin (IL) 1, IL6, and tumor necrosis factor-α. These cytokines get transferred into the bloodstream and cause excessive capillary permeability through the dilatation of smooth muscles [Figure 6]. This vasodilation and increased permeability allow leaking out the plasma and other fluids in interstitial spaces of alveoli leading to alveolar edema hence alveolar collapse and hypoxemia. Due to the release of inflammatory mediators, the multiple organs get influenced to show the abnormalities in the prodromal phase as the major clinical symptoms of high fever, dry cough, high blood pressure, fatigue, myalgia, diarrhea, dyspnea, lymphopenia, RNAaemia, respiratory distress syndrome, secondary superinfections, and acute cardiac injuries.[7]

Figure 6.

Figure 6

Binding and replication of coronavirus disease-2019 leading to release and alveolar collapse. The figure is made with BioRender (https://biorender.com/)

TREATMENT AND MANAGEMENT

At the time of preparing this manuscript, there is still no specific treatment available for COVID-19. Despite the facts of minimal recoveries and having no choice, the Food and Drug Administration approved chloroquine and hydroxychloroquine (an antimalarial drug) to be effective somehow as the remedial approach.[28] The treatment is symptomatic; major treatment interventions are mechanical ventilation, hemodynamic support, and oxygen therapy for patients with severe infection. One of the antiviral (lopinavir 400 mg or ritonavir 100 mg BD) treatment approaches has been recommended and aerosol formulation of alpha-interferon twice daily proposed.[29] Other drugs that are widely used around the world to control the complications are fingolimod, methylprednisolone, chloroquine phosphate, hydroxychloroquine sulfate, bevacizumab, leronlimab, ivermectin, and sarilumab. Corona-infected patients can be managed with rehydration therapy, respiratory inhalation therapy, and providing aid to the affected vital organs.[30]

Awareness and dedication can only minimize the spread rate of COVID-19 by strengthening the trust within the communities without having any fear of failure.[31] Strategic recommendations also include the isolation protocols along with the proper use of N95 or FFP3 masks, eye-protective glass, apron, and gloves to prevent the pathogens move [Figure 7].[32]

Figure 7.

Figure 7

An illustration showing the mode of transmission, clinical symptoms and preventive and safety measures for coronavirus disease-2019. The figure is made with BioRender (https://biorender.com/)

SOCIAL DISTANCING IMPACT

Due to the corona pandemic, several countries have declared a state emergency, including developed countries, even having the best infrastructure of the health-care system, which has raised concerns about lasting impacts on civil liberties. Worldwide with social distancing, the most affected system is educational institutes that leads to almost closure of universities, schools, and colleges, which negatively impact learning outcomes. The impact was more distressing for underprivileged children and their families, causing intersperse learning, inadequate nutrition, infant care problems, and subsequent economic expenditure to family members who could not work. This pandemic also affected the financial markets.

PSYCHOLOGICAL IMPACT

This pandemic has a severe psychological impact including a significant degree of mental stress, fear, anxiety, and worry in most of the public, health caregivers, as well as in a specific group of comorbid diseased populations. Stress during this pandemic can comprises concern and fear about health and health condition of relatives, changing and diet practices, trouble in sleeping or concentration, deterioration of chronic health issues, and deteriorating psychological health situations, increase consumption of alcohol, tobacco, or other drugs.[33]

VACCINE DEVELOPMENT

Research scientists throughout the world have been struggling to develop powerful vaccines against COVID-19. Inactivated or weakened virus vaccine, protein-based vaccines, RNA and DNA vaccines, and viral vector vaccines are the types of potential vaccines that are in development. Several vaccines are currently available to overcome this pandemic which include Pfizer-BioNTech, Sinopharm (China), Johnson and Johnson, Novavax (UK), Astrazeneca, Sinovac (China), CanSinoBio, and Gamaleya Research Institute (Russia) [Table 2]. The vaccine for the COVID-19 was first started in December 2020 and until February 15, 2021, 175.3 million vaccine doses have been given. The emergency use licenses were also issued for some vaccines such as Pfizer, AstraZeneca/Oxford, and vaccine developed by Johnson and Johnson. The side effects of the vaccines have also been reported. Thirty-three suspected adverse drug reactions have been found in Norway including some fatal responses after the use of BioNTech and Pfizer vaccines as per the Norwegian Medicines Agency.[34]

Table 2.

Coronavirus disease-2019 candidate vaccines in clinical evaluation

COVID-19 Vaccine developer/manufacturer Vaccine platform Type of candidate vaccine Number of doses Timing of doses Route of Administration
Sinovac Inactivated Inactivated 2 0, 14 days IM
Wuhan Institute of Biological Products/Sinopharm Inactivated Inactivated 2 0,21 days IM
Beijing Institute of Biological Products/Sinopharm Inactivated Inactivated 2 0,21 days IM
University of Oxford/AstraZeneca Non- Replicating Viral Vector ChAdOx1-S 1 IM
CanSino Biological Inc./Beijing Institute of Biotechnology Non- Replicating Viral Vector Adenovirus Type 5 Vector 1 IM
Gamaleya Research Institute Non- Replicating Viral Vector Adeno-based (rAd26-S + rAd5-S) 2 0,21 days IM
Janssen Pharmaceutical Companies Non- Replicating Viral Vector Ad26COVS1 2 0, 56 days IM
Novavax Protein Subunit Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M 2 0, 21 days IM
Moderna/NIAID RNA LNP-encapsulated mRNA 2 0, 28 days IM
BioNTech/Fosun Pharma/Pfizer RNA 3 LNP-mRNAs 2 0, 28 days IM
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences Protein Subunit Adjuvanted recombinant protein (RBD-Dimer) 2 or 3 0,28 or 0,28, 56 days IM
Curevac RNA mRNA 2 0, 28 days IM
Institute of Medical Biology, Chinese Academy of Medical Sciences Inactivated Inactivated 2 0, 28 days IM
Research Institute for Biological Safety Problems, Rep of Kazakhstan Inactivated Inactivated 2 0, 21 days IM
Inovio Pharmaceuticals/International Vaccine Institute DNA DNA plasmid vaccine with electroporation 2 0, 28 days ID
Osaka University/AnGes/Takara Bio DNA DNA plasmid vaccine + Adjuvant 2 0, 14 days IM
Cadila Healthcare Limited DNA DNA plasmid vaccine 3 0, 28, 56 days ID
Genexine Consortium DNA DNA Vaccine (GX-19) 2 0, 28 days IM
Bharat Biotech Inactivated Whole-Virion Inactivated 2 0, 14 days IM
Kentucky Bioprocessing, Inc Protein Subunit RBD-based 2 0, 21 days IM
Sanofi Pasteur/GSK Protein Subunit S protein (baculovirus production) 2 0, 21 days IM
Arcturus/Duke-NUS RNA mRNA IM
SpyBiotech/Serum Institute of India VLP RBD-HBsAg VLPs 2 0, 28 days IM
ReiThera/LEUKOCARE/Univercells Non- Replicating Viral Vector Replication defective Simian Adenovirus (GRAd) encoding S 1 IM
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China Non- Replicating Viral Vector Ad5-nCoV 2 0, 28 days IM/mucosal
Vaxart Non- Replicating Viral Vector Ad5 adjuvanted Oral Vaccine platform 2 0, 28 days Oral
Ludwig-Maximilians - University of Munich Non- Replicating Viral Vector MVA-SARS-2-S 2 0, 28 days IM
Clover Biopharmaceuticals Inc./GSK/Dynavax Protein Subunit Native like Trimeric subunit Spike Protein vaccine 2 0, 21 days IM
Vaxine Pty Ltd/Medytox Protein Subunit Recombinant spike protein with Advax™ adjuvant 1 IM
University of Queensland/CSL/Seqirus Protein Subunit Molecular clamp stabilized Spike protein with MF59 adjuvant 2 0, 28 days IM
Medigen Vaccine Biologics Corporation/NIAID/Dynavax Protein Subunit S-2P protein + CpG 1018 2 0, 28 days IM
Instituto Finlay de Vacunas, Cuba Protein Subunit RBD + Adjuvant 2 0, 28 days IM
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo Protein Subunit Peptide 2 0, 21 days IM
West China Hospital, Sichuan University Protein Subunit RBD (baculovirus production expressed in Sf9 cells) 2 0, 28 days IM
University Hospital Tuebingen Protein Subunit SARS-CoV-2 HLA-DR peptides 1 SC
COVAXX Protein Subunit S1-RBD-protein 2 0, 28 days IM
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme Replicating Viral Vector Measles-vector based 1 or 2 0, 28 days IM
Beijing Wantai Biological Pharmacy/Xiamen University Replicating Viral Vector Intranasal flu-based-RBD 1 IM
IMperial College London RNA LNP-nCoVsaRNA 2 IM
People’s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. RNA mRNA 2 0, 14 or 0, 28 days IM
Medicago Inc. VLP Plant-derived VLP adjuvanted with GSK or Dynavax adjs. 2 0, 21 days IM

COVID-19 Vaccine developer/manufacturer Clinical Stage

Phase 1 Phase 1/2 Phase 2 Phase 3

Sinovac NCT04383574
NCT04352608
NCT04551547
NCT04456595 669/UN6.KEP/EC/2020
Wuhan Institute of Biological Products/Sinopharm ChiCTR2000031809
Interim Report
ChiCTR2000034780
Beijing Institute of Biological Products/Sinopharm ChiCTR2000032459 ChiCTR2000034780
NCT04560881
University of Oxford/AstraZeneca PACTR202006922165132 2020-001072-15
NCT04568031
Interim Report
2020-001228-32 ISRCTN89951424 NCT04516746 NCT04540393 CTRI/2020/08/027170
CanSino Biological Inc./Beijing Institute of Biotechnology ChiCTR2000030906 Study Report ChiCTR2000031781 Study Report NCT04526990
NCT04540419
Gamaleya Research Institute NCT04436471 NCT04437875 Study Report NCT04530396 NCT04564716
Janssen Pharmaceutical Companies NCT04436276 NCT04505722
Novavax NCT04368988 Study Report NCT04533399 (phase 2b) 2020-004123-16
Moderna/NIAID NCT04283461
Interim Report Final Report
NCT04405076 NCT04470427
BioNTech/Fosun Pharma/Pfizer 2020-001038-36 ChiCTR2000034825 NCT04537949 Study Report NCT04368728
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences NCT04445194 NCT04550351 NCT04466085
Curevac NCT04449276 NCT04515147
Institute of Medical Biology, Chinese Academy of Medical Sciences NCT04412538 NCT04470609
Research Institute for Biological Safety Problems, Rep of Kazakhstan NCT04530357
Inovio Pharmaceuticals/International Vaccine Institute NCT04447781 NCT04336410
Osaka University/AnGes/Takara Bio NCT04463472 NCT04527081
Cadila Healthcare Limited CTRI/2020/07/026352
Genexine Consortium NCT04445389
Bharat Biotech NCT04471519 CTRI/2020/09/027674
Kentucky Bioprocessing, Inc NCT04473690
Sanofi Pasteur/GSK NCT04537208
Arcturus/Duke-NUS NCT04480957
SpyBiotech/Serum Institute of India ACTRN12620000817943
ReiThera/LEUKOCARE/Univercells NCT04528641
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China NCT04552366
Vaxart NCT04563702
Ludwig-Maximilians - University of Munich NCT04569383
Clover Biopharmaceuticals Inc./GSK/Dynavax NCT04405908
Vaxine Pty Ltd/Medytox NCT04453852
University of Queensland/CSL/Seqirus ACTRN12620000674932p ISRCTN51232965
Medigen Vaccine Biologics Corporation/NIAID/Dynavax NCT04487210
Instituto Finlay de Vacunas, Cuba IFV/COR/04
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo NCT04527575
West China Hospital, Sichuan University ChiCTR2000037518
University Hospital Tuebingen NCT04546841
COVAXX NCT04545749
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme NCT04497298
Beijing Wantai Biological Pharmacy/Xiamen University ChiCTR2000037782
IMperial College London ISRCTN17072692
People’s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. ChiCTR2000034112
Medicago Inc. NCT04450004

COVID-19: Coronavirus disease-2019, PLA: People’s liberation army, SARS: Severe acute respiratory syndrome, CoV-2: Coronavirus-2, HLA: Human leukocyte antigen, DR: D related, RBD: Receptor-binding domain

CONCLUSION

More than 15 months passed of this pandemic, some nonpharmacological approaches have been adopted to combat the symptoms of the disease. As a result of this, only social distancing, quarantine, and isolation methods are advised to keep away from the infections. It also leads to a negative impact on the psychological behavior of human beings.

The scientific community has led to the development more than 40 vaccines that are undergoing the clinical trials, including more than 10 in phase III trials and three of them is ended with the positive results. The world is expecting that this vaccination program will be a significant measure to eradicate this pandemic. Other challenges that still need to be addressed are the multiple variants of this virus that is emerging day by day.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  • 1.Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) In: StatPearls. FL, USA: StatPearls Publishing; 2020. [PubMed] [Google Scholar]
  • 2.Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–36. doi: 10.1080/22221751.2020.1719902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health–The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264. doi: 10.1016/j.ijid.2020.01.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mahtani S, Berger M, O'Grady S, Iati M. Hundreds of Evacuees to be Held on Bases in California; Hong Kong and Taiwan Restrict Travel from Mainland China. The Washington Post. 2020. [[Last accessed on 2020 Feb 11]]. Available from: https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/02/05/114ced8a-479c-11eabc78-8a18f7afcee7_story.html .
  • 5.WHO. WHO Director-General's Opening Remarks at the Media Briefing on COVID-19”. World Health Organization (WHO) (Press Release) [[Last accessed on 2020 Mar 11]]. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingoncovid-19-11-march-2020.
  • 6.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207. doi: 10.1056/NEJMoa2001316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci Trends. 2020;14:69–71. doi: 10.5582/bst.2020.01020. [DOI] [PubMed] [Google Scholar]
  • 9.Anonymous. [[Last accessed on 2020 Mar 05]]. Available from: https://www.cdc.gov.tw/En .
  • 10.Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92:441–7. doi: 10.1002/jmv.25689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Anonymous. [[Last accessed on 2020 Mar 10]]. https://www.who.int/docs/default-source/coronaviruse/situationreports.
  • 12.Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164. doi: 10.1016/B978-0-12-385885-6.00009-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. BioRxiv. 2020 https://doi.org/10.1101/2020.01.24.919183. [Google Scholar]
  • 14.Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565–74. doi: 10.1016/S0140-6736(20)30251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:1–17. doi: 10.3390/v12040372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–7. doi: 10.1056/NEJMc2004973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020;382:1653–9. doi: 10.1056/NEJMsr2005760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–9. doi: 10.1161/01.res.87.5.e1. [DOI] [PubMed] [Google Scholar]
  • 19.Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–60. doi: 10.1007/s11427-020-1637-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69:1002–9. doi: 10.1136/gutjnl-2020-320926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Anonymous. 2020. [[Last accessed on 2020 Mar 20]]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance .
  • 22.Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology. 2020;296:E32–40. doi: 10.1148/radiol.2020200642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–9. doi: 10.1038/nm1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85:4122–34. doi: 10.1128/JVI.02232-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2021;54:159–63. doi: 10.1016/j.jmii.2020.03.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens. 2020;9:1–14. doi: 10.3390/pathogens9030231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71. doi: 10.1038/s41422-020-0282-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008;105:16119–24. doi: 10.1073/pnas.0805240105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fisher D, Heymann D. Q and A: The novel coronavirus outbreak causing COVID-19. BMC Med. 2020;18:57. doi: 10.1186/s12916-020-01533-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Alexander N, Gibbons K, Marshall S, Rodriguez M, Sweitzer J, Varma K. Implementing Principles of Reimagine Minnesota in a Period of Remote Teaching and Learning: Education Equity in the Age of COVID-19; Minneapolis Foundation, MN, US. 2020 [Google Scholar]
  • 32.Ahmad MD, Wahab S, Ali Ahmad F, Intakhab Alam M, Ather H, Siddiqua A, et al. A novel perspective approach to explore pros and cons of face mask in prevention the spread of SARS-CoV-2 and other pathogens. Saudi Pharm J. 2021;29:121–33. doi: 10.1016/j.jsps.2020.12.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res. 2020;17:1729. doi: 10.3390/ijerph17051729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ. 2021;372:n149. doi: 10.1136/bmj.n149. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Advanced Pharmaceutical Technology & Research are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES